Cargando…

MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer

The immune checkpoint ligand programmed death-ligand 1 (PD-L1) and the transmembrane mucin (MUC) 3A are upregulated in non-small cell lung cancer (NSCLC), contributing to the aggressive pathogenesis and poor prognosis. Here, we report that knocking down the oncogenic MUC3A suppresses the PD-L1 expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yuan, Ma, Shijing, Sun, Yingming, Peng, Shan, Zeng, Zihang, Han, Linzhi, Li, Shuying, Sun, Wenjie, Xu, Jieyu, Tian, Xiaoli, Wang, Feng, Wu, Qiuji, Xiao, Yu, Zhang, Junhong, Gong, Yan, Xie, Conghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120466/ https://www.ncbi.nlm.nih.gov/pubmed/33994852 http://dx.doi.org/10.7150/ijbs.57964

Ejemplares similares

Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration
por: Xu, Jieyu, et al.
Publicado: (2020)

MUC3A promotes non-small cell lung cancer progression via activating the NFκB pathway and attenuates radiosensitivity
por: Sun, Yingming, et al.
Publicado: (2021)

MUC3A promotes non-small cell lung cancer progression via activating the NFκB pathway and attenuates radiosensitivity
por: Sun, Yingming, et al.
Publicado: (2022)

Small Nucleolar RNA 71A Promotes Lung Cancer Cell Proliferation, Migration and Invasion via MAPK/ERK Pathway
por: Tang, Guiliang, et al.
Publicado: (2019)

Immunomodulation of NK Cells by Ionizing Radiation
por: Chen, Jiarui, et al.
Publicado: (2020)

MFP-FePt-GO Nanocomposites Promote Radiosensitivity of Non-Small Cell Lung Cancer Via Activating Mitochondrial-Mediated Apoptosis and Impairing DNA Damage Repair
por: Peng, Shan, et al.
Publicado: (2020)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
por: Takahashi, Satoshi, et al.
Publicado: (2021)

FePt/GO Nanosheets Suppress Proliferation, Enhance Radiosensitization and Induce Autophagy of Human Non-Small Cell Lung Cancer Cells
por: Ma, Shijing, et al.
Publicado: (2019)

Agrin Promotes Non-Small Cell Lung Cancer Progression and Stimulates Regulatory T Cells via Increasing IL-6 Secretion Through PI3K/AKT Pathway
por: Han, Linzhi, et al.
Publicado: (2022)

Protective Role of Nuclear Factor-Erythroid 2-Related Factor 2 Against Radiation-Induced Lung Injury and Inflammation
por: Tian, Xiaoli, et al.
Publicado: (2018)

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
por: Ray, Paramita, et al.
Publicado: (2016)

Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis
por: Ouyang, Wen, et al.
Publicado: (2020)

The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
por: Luna, Herdee Gloriane C., et al.
Publicado: (2023)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells
por: You, Chengcheng, et al.
Publicado: (2018)

HHLA2 deficiency inhibits non‐small cell lung cancer progression and THP‐1 macrophage M2 polarization
por: Sun, Wenjie, et al.
Publicado: (2021)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application
por: Sun, Wenjie, et al.
Publicado: (2019)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma
por: Han, Linzhi, et al.
Publicado: (2020)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts
por: Zeng, Zihang, et al.
Publicado: (2022)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)
por: He, Jingyi, et al.
Publicado: (2021)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
por: Gao, Yanping, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
por: Cansouline, Xavier, et al.
Publicado: (2022)

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Xia, Jinjing, et al.
Publicado: (2017)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_atdgtu7a2ru5l36irceaat4bhi